Site icon Theratome

Theratome Bio Received Grant Award

Theratome Bio has received a Small Business Technology Transfer Grant (STTR) grant from the National Institutes of Health (NIH) to study its technology for treatment of urinary incontinence, a major unmet
medical need in women’s health that represents a $3B market. Injury to the pelvic floor sustained during childbirth, combined with the effects of menopause, is a key factor underlying female urinary incontinence. The grant will fund research in this specific area with the goal to optimize the technology for clinical application.
The research project will be conducted in collaboration with researchers at the Cleveland Clinic. Margot Damaser, PhD, a leader in the field of incontinence research, is the principle investigator on the project at the Lerner College of Medicine and will spearhead the research in her lab. Dr. Damaser has previously demonstrated that the secretome from stem cells is highly effective for treating pelvic floor injury in animal models. Theratome Bio’ s technology is a cell-free, off-the-shelf, easy-to-administer therapy without the immunogenicity, storage and distribution challenges associated with cell therapies.
In addition to receiving the maximum amount allowed for this type of NIH award, Theratome Bio has also received state sponsored matching funds via the partnership between the Indiana Economic Development Corporation (IEDC) and Elevate Ventures.

Exit mobile version